Ricciuti B, et al. - Given a link between baseline use of corticosteroids and poor outcomes has been reported in patients with non–small-cell lung cancer (NSCLC) who received programmed cell death-1 axis inhibition, researchers performed this study to approach the question of causation vs correlation for this link. For this purpose, they assessed results in immunotherapy treated NSCLC cases based on whether corticosteroids were given for cancer-related palliative reasons or cancer-unrelated indications. Findings revealed worse outcomes in NSCLC patients who received ≥ 10 mg of prednisone at the time of immunotherapy initiation vs those treated with 0 to < 10 mg of prednisone; a poor-prognosis subgroup of patients treated with corticosteroids for palliative indications seemed to be the driver of this difference.